PMC8077448_01
a Appearance of the breast mass at presentation. Image of the breast lesion illustrating the fungating breast ulcer on a large and irregularly shaped right breast mass. b Computed tomography image at presentation revealing a large right breast tumor with skin ulceration and bilateral axillary lymph node metastases.
cro-0014-0580-g01.jpg
PMC8077448_01_cro-0014-0580-g01.jpg
F1
She had a right breast lump with 15 cm of skin ulceration as well as bleeding, fungation, and odor at presentation (Fig. 1a). Computed tomography revealed a right breast tumor with skin ulceration, bilateral axillary lymph node metastases (Fig. 1b), and multiple lung metastases.
a Appearance of the breast mass after the administration of bevacizumab and paclitaxel. b Computed tomography image after the use of Mohs' paste and the administration of bevacizumab and paclitaxel.
cro-0014-0580-g02.jpg
PMC8077448_01_cro-0014-0580-g02.jpg
F2
Six months after the administration of bevacizumab and paclitaxel, tumor regrowth was observed, leading to the diagnosis of disease progression even though the primary tumor was smaller than its initial size at presentation (Fig. 2).
a Appearance of the breast mass after the administration of eribulin. b Computed tomography image after the use of Mohs' paste and the administration of eribulin. c Appearance of the breast mass after mastectomy and skin grafting.
cro-0014-0580-g03.jpg
PMC8077448_01_cro-0014-0580-g03.jpg
F3
Two months after the administration of eribulin, a partial response was obtained, although tumor effusion was still observed (Fig. 3a, b). After surgery, she experienced significant improvement in QoL based on the elimination of bleeding and odor, and she did not need to replace her bandages daily (Fig. 3c).